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Abstract 
Understanding genetic factors that contribute to cannabis addiction is important, but to date, findings 
have been equivocal. Single nucleotide polymorphisms in the Cannabinoid receptor 1- gene (CNR1; 
rs1049353, rs806378) and the Fatty Acid Amide Hydrolase (FAAH) gene (rs324420) have been 
implicated in the development of addiction. Their relationship to addiction endophenotypes such as 
drug-cue salience, state satiety and craving after acute cannabinoid administration has not been 
investigated. Forty-eight cannabis users participated in a double-blind, placebo-controlled, four-way 
crossover study where they were administered 4 treatments in a randomised order via vaporisation: 
placebo, Δ9-tetrahydrocannabinol (THC) (8mg), THC+Cannabidiol (CBD) (8mg + 16mg), CBD (16mg). 
Salience of appetitive cues (cannabis, food), state satiety and cannabis cravings were assessed each 
day. Participants were genotyped for rs1049353, rs806378 and rs324420. Results indicated CNR1 
rs1049353 GG carriers showed reduced salience to appetitive cues after THC in comparison to CBD 
administration. GG carriers showed reduced state satiety after THC and THC+CBD administration, in 
comparison to placebo; A carriers did not vary on either of these measures. CNR1 rs806378 CC carriers 
showed greater bias to appetitive cues in comparison to T carriers but there was no evidence for 
changes in state satiety. FAAH rs324420 A carriers showed greater bias to appetitive cues after THC, 
in comparison to CC carriers. FAAH CC carriers showed reduced bias after THC in comparison to CBD. 
None of the genes modulated craving. These findings show that endocannabinoid system genetics can 
modulate addiction endophenotypes after acute administration of cannabinoids in healthy 
individuals.  
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Introduction 
Problematic drug use is influenced by both environmental and genetic factors with genetic variation 
accounting for between ~40 to 60% of the variance of the total risk in vulnerable individuals (Nestler 
and Landsman 2001). Policies about cannabis use worldwide are becoming more liberal. 
Understanding the individual differences in vulnerability and resilience to the harmful effects of 
cannabis is a critically important aim as cannabis stands poised to join alcohol and tobacco as a legal 
drug across the globe (Curran et al. 2016), whereby rates of addiction to cannabis may also rise (Pacula 
et al. 2015). The endocannabinoid system is fundamental in drug addiction (Volkow et al. 2017). 
Genetic differences in the endocannabinoid system may contribute to an individual’s vulnerability or 
resilience to cannabis addiction.  
The primary psychoactive cannabinoid in cannabis, Δ9-tetrahydrocannabinol (THC), is a partial agonist 
at the endocannabinoid receptor type 1 (CB1R). THC is the primary driver of the addictive effects of 
cannabis (affecting 9% of those who initiate use (Lopez-Quintero et al. 2011)). The percentage of THC 
in cannabis has been increasing over the past two decades (ElSohly et al. 2016) which may be related 
to increased rates of cannabis dependence (Freeman et al. 2018). Cannabidiol (CBD), the second most 
abundant cannabinoid found in the cannabis plant is non-intoxicating (Hindocha et al. 2015a) and non-
rewarding (Babalonis et al. 2016; Haney et al. 2015), has psychopharmacologically opposite effects to 
THC (Bloomfield et al. 2018; Curran et al. 2016; Parsons and Hurd 2015), but its mechanism of action 
has not fully been determined. Some research suggests it is a negative allosteric modulator of the 
CB1R (Laprairie et al. 2015); and/or increases the inhibition of Fatty Acid Amide Hydrolase (FAAH), 
which is an indirect mechanism of regulating the activity of the CB1R (Pertwee 2008). The ratio of 
THC:CBD is important for its addictive potential, as CBD protects against the addiction-related and 
psychotic-like effects of THC (Di Forti et al. 2016; Englund et al. 2013; Morgan et al. 2012; Morgan et 
al. 2010; Schubart et al. 2011; Zuardi et al. 1982).  
The CNR1 gene encodes the CB1R and is located on chromosome 1 (López-Moreno et al. 2012). Meta-
analyses have found that polymorphisms in CNR1 have been associated with cannabis  (Agrawal et al. 
2009; Benyamina et al. 2011; Hartman et al. 2009; López-Moreno et al. 2012), alcohol (Schmidt et al. 
2002), nicotine (Chen et al. 2008) and cocaine dependence (Clarke et al. 2013).  Polymorphisms in the 
CNR1 are also associated with potential endophenotypes related to cannabis dependence such as 
functional reward-related brain activity during exposure to cannabis cues (Filbey et al. 2010). As such, 
genetic influences may therefore alter mechanisms related to addiction – such as craving, satiation 
and the salience of drug cues.  
Endocannabinoid signalling is terminated by enzymes such as FAAH which catabolises the endogenous 
cannabinoid, anandamide. FAAH inhibition is a mechanism that is currently being investigated as a 
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treatment of addiction in animals and humans (D'Souza et al. 2015; Hindocha et al. 2018; Justinova et 
al. 2015; Panlilio et al. 2013). The rs324420 Single Nucleotide Polymorphism (SNP) of the FAAH enzyme 
is a C to A polymorphism which results in a proline to a threonine substation at codon 129 (López-
Moreno et al. 2012). As such, those with the A allele have reduced FAAH expression (Chiang et al. 
2004; Sipe et al. 2002). This reduction has been associated with problematic drug use (Flanagan et al. 
2006; Sipe et al. 2002) and putative endophenotypes such as craving and withdrawal after short-term 
abstinence (Schacht et al. 2009). However, the C allele has also been associated with cannabis 
dependence in Genome Wide Association Studies (GWAS) (Flanagan et al. 2006) as well as other 
potential endophenotypes such as greater craving and withdrawal after cannabis abstinence (Haughey 
et al. 2008; Schacht et al. 2009). Additionally, Filbey et al. (2010) found that those who were 
homozygous for the C allele showed greater activation in the reward circuit (which included the 
orbitofrontal cortex, anterior cingulate gyrus and the nucleus accumbens) after cannabis cue 
reactivity, in comparison to A allele carriers. However, no studies have investigated how genes related 
the endocannabinoid system predict addiction-related endophenotypes after controlled acute 
administration of cannabinoids.  
Our innovative approach was to study endophenotypes of addiction after acute cannabinoid 
administration, which may be more valid than a single dichotomous variable commonly used in GWAS 
(Flint and Munafò 2007; Gottesman and Gould 2003). We focussed upon three endophenotypes of 
addiction. Firstly, attentional processing is an important transdiagnostic marker for depression, 
anxiety and addiction (Garland and Howard 2014; Hindocha et al. 2018). Indeed, THC:CBD ratio 
predicts attentional bias to cannabis cues when intoxicated, with those using more CBD in their 
cannabis strains showing reduced attentional bias (Morgan et al. 2010). The salience of appetitive 
stimuli (such as cannabis cues to cannabis-dependent individuals) is also related to frequency of 
cannabis use; dependence on the drug itself, and craving (Field 2005; Field and Cox 2008; Field et al. 
2004).  Secondly, craving, or the intense desire for a reward, is a primary behavioural component of 
addiction (Filbey et al. 2009) which motivates drug use and predicts cannabis use after 6 months in 
adults and adolescents (Cousijn et al. 2011; Cousijn et al. 2015). Thirdly, satiation after acute ingestion 
of a drug is a key element of addiction and is likely related to loss of control measures, such that not 
feeling satiety after acute drug use may be a key indicator of addiction (Sussman and Sussman 2011).  
 Our primary aim was to investigate if and how genetic variants in the endocannabinoid system, in 
particular the CB1 receptor (rs1049353 and rs806378) and the FAAH enzyme (rs324420) would 
modulate the acute response to cannabis, in relation to promising addiction endophenotypes: drug 
cue salience, satiation and craving.  To this end, we carried out a randomised, double-blind, crossover 
study where participants were administered THC (8 mg), THC (8 mg)+CBD (16 mg), CBD (16 mg) and 
placebo (ethanol vehicle) across four separate sessions. We predicted that genetic variants in the CB1 
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receptor and FAAH enzyme would modulate acute response to THC in regards to these 
endophenotypes. Moreover, given research that suggests that CBD protects against the addiction-
related effects of THC (Morgan et al 2010), differential effects of drug conditions were expected on 
addiction endophenotypes, although how this would interact with endocannabinoid genotypes was 
exploratory, given the paucity of research in this area. 
Material and Methods 
Participants  
Participants were recruited on the basis of having previously volunteered in a large scale study of over 
400 cannabis users (Morgan et al. 2012) where genotyping was conducted (Morgan et al. 2016).  
Participants were recruited based on 1) schizotypy (Schizotypal Personality Questionnaire score (top 
and bottom quartiles)) and 2) Frequency of cannabis use (“light” = 1-24 days per month; “heavy” =  
25+ days per month). This study is a secondary analysis concerned with genetic associations across 
the whole sample regardless of sub-group. Additional data from this study on facial affect recognition 
and visual analogue scales (Hindocha et al. 2015a) and psychotomimetic symptoms and memory 
function have been reported elsewhere (Morgan et al. 2018). 
Participants were matched for age and Spot the Word task (Baddeley et al. 1993) scores across 
frequency groups. Inclusion criteria were: (i) self-reported abstinence from cannabis, other drugs and 
alcohol use for 24h prior to each test day; (ii) English fluency, (iii) normal or corrected to normal vision. 
Exclusion criteria were: current self-reported (i) respiratory health problems/physical health 
problems, (ii) pregnancy or the risk of being pregnant, (iii) clinically diagnosed learning impairments, 
(iv) clinically diagnosed schizophrenia/psychosis or substance abuse problems, and (v) no illicit drug 
use other than cannabis more than once a week. 
Design 
A four session, randomised, double-blind crossover design was used to compare the acute effects of 
THC (8mg), CBD (16mg) and their combination (8mg THC+16mg CBD) with placebo (ethanol vehicle). 
Both cannabinoids were formulated in alcohol solution and were purchased from STI Pharmaceuticals 
(Brentwood, Essex, UK). Treatment order across the 4 sessions was determined by a balanced Latin 
square resulting in 12 combinations. 
Drug administration 
Cannabinoids and placebo (ethanol vehicle) were administered using a Volcano Medic Vaporisor 
(Storz & Bickel, Tuttlingen, Germany). 8mg THC dissolved in ethanol and 16mg of CBD dissolved in 
ethanol were administered on a 10-second inhalation cycle wherein participants was instructed to 
first fully exhale, next fully inhale from the balloon, hold their breath for 10 seconds and then fully 
exhale; this was repeated until the balloon was empty. Justification of doses and further details about 
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drug administration and concealment and blinding can be found in Hindocha et al. (2015a) and 
Morgan et al. (2018). 
Genotyping 
DNA was obtained from cheek swabs of all participants who completed the assessments described 
above. DNA extraction was performed using standard phenol–chloroform methods. Analyses were 
performed on two SNPs of CNR1: rs1049353, rs806378 and one single-nucleotide polymorphism of 
the FAAH gene (rs324420). Off the shelf Taqman assays for these polymorphisms are available as a kit 
(Applied Biosystems, Life Technologies, Paisley, UK). Genotype calls were discriminated on the basis 
of algorithmic membership of three clusters representing homozygote A/A, heterozygote A/G, and 
homozygote G/G genotype classes for CNR1 rs1049353, C/C, C/T and T/T for CNR1 rs806378 and 
CC/AC/AA for FAAH rs324420. Individuals with the minor allele of these SNPS were combined for 
power and due to the rarity of these alleles. For rs1049353, those with the minor allele of A, were 
combined with heterozygotes AG according to convention (Agrawal et al. 2012a; Domschke et al. 
2008). For CNR1 rs806378, those with the minor allele T were combined with heterozygotes CT (Tiwari 
et al. 2010) and for FAAH rs324420, the minor allele A, was combined with the heterozygote AC 
(Spagnolo et al. 2016). Data was missing for 6 individuals for rs1049353, 3 individuals for rs806378 
and 4 individuals for rs324420 
Assessments 
Before drug administration, participants completed the Beck Depression Inventory (Beck et al. 1961), 
Spielberger Trait Anxiety Inventory (Spielberger et al. 1970), Schizotypal Personality Questionnaire 
(Raine 1991), Severity Of Dependence Scale (Gossop et al. 1995) and a drug history (Curran et al. 2018; 
Hindocha et al. 2015a; Hindocha et al. 2017; Hindocha et al. 2015b; Morgan et al. 2018).  
Dot Probe task (Fig 1) 
Adapted from Morgan et al. (2010), this computer-based dot-probe paradigm was used to assess 
attentional bias to both cannabis- and food-related stimuli. Ten colour photographs of cannabis-
related stimuli and 10 colour photographs of food-related stimuli were used, with each image 
simultaneously paired with a neutral photograph matched as closely as possible for visual composition 
and complexity. A total of 80 of the 160 total trials were critical trials of which 40 featured cannabis-
related and 40 food-related stimuli, each presented twice for 250ms. Based on findings in Morgan et 
al. (2010), only the short exposure time was chosen to index automatic (250 ms) processing. The 
critical (food- or cannabis-related) images appeared once on the left and once on the right at each 
time interval. The side at which the probe appeared was counterbalanced across all the trials. An 
asterisk was used as the probe. A total of 10 neutral practice trial pairs were used as training, followed 
by two blocks of 80 experimental trials. Short break occurred between blocks. Versions were 
randomised across testing days. Each trial began with a central fixation cross shown for 1000 ms, after 
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which a pair of matched images would appear, one on each side of the fixation cross, for 250 ms 
durations. Both images then disappeared revealing the probe behind one of the two images. The task 
took place approximately 25 minutes after drug administration. Participants were required to respond 
to the probe as quickly as possible by pressing a button corresponding to the relevant side of the 
screen. Attentional bias was calculated as the difference in reaction time between when the probe 
replaced the neutral compared with the incentive (cannabis/food) stimulus [Rtneutral-RTincentive], 
such that a greater difference indicated greater bias toward that stimulus.  
 
Figure 1. Trial structure for the visual probe task. Example of Cannabis (right) and matched neutral 
stimuli (left) provided 
Bodily Symptoms Scale (BSS) (Bond and Lader 1974): “want to smoke a joint” single item.  
The BSS was designed to detect physical symptoms of acute cannabinoids administration. Participants 
rated on scale from 0 (do not want to smoke a joint) to 10 (really want a joint), how much they wanted 
to smoke a joint both 10 and 70 minutes post drug administration. This measure was used to index 
state satiation. 
Marijuana craving questionnaire (Heishman et al. 2009) 
 A short 12-item questionnaire was given to assess current craving for cannabis. Participants 
completed the MCQ immediately after the attentional bias task; approximately 35 minutes after drug 
administration. The MCQ is reliable for assessing craving in cannabis users not seeking treatment 
(Heishman et al. 2001). 
Procedure 
Experimental sessions occurred on four occasions each separated by a one-week washout to minimize 
carry-over effects (>3 times elimination half-life of THC (Hindocha et al. 2015a)). We used urine and 
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saliva screens to verify drug use. Participants completed assessments then two minutes after drug 
administration. The full test battery took approximately 1.5 hours on each test day. Participants were 
reimbursed £120 for their time on the last testing day and debriefed fully. All participants provided 
written, informed consent on each occasion and ethical approval was given by the UCL Research Ethics 
Committee.  
Statistical analysis 
All analyses were conducted with SPSS 24.0. Syntax are available from CH on request. Outliers and 
normality were assessed via diagnostic plots. Extreme outliers (>3 times interquartile range) were 
winsorized within-group to the next highest/lowest value +/- 1. Descriptive statistics based on 
genotype were conducted with one way analysis of variance (ANOVA) and Chi-Squared Tests. When 
variances were not equal between groups (Levene’s test), unequal variances (Welch’s) t-tests were 
used.   
Mixed ANOVA was used for all analyses with a within-subjects factor of drug (placebo, THC, 
THC+CBD, CBD) and a between-subjects factor of genotype. Greenhouse Geisser corrections were 
applied for violations of sphericity (rounded to the nearest whole number). For attentional bias, 
there was an additional within-subjects factor of stimulus type (cannabis, food), for BSS “want to 
smoke a joint”, the additional within-subject factor was time (T1, T2). Main effects were explored 
with a priori simple contrasts to reduce the number of comparisons (e.g. for the main effect of drug 
this was; placebo vs. THC, placebo vs. THC+CBD and placebo vs. CBD). Interactions were explored 
with Bonferroni-corrected pairwise comparisons locally within each omnibus term. η² was calculated 
as the SSeffect/SStotal.  
Results  
Sample Characteristics (Table 1) 
CNR1 rs1049353 genotypes were in Hardy-Weinberg equilibrium (G/G=20, A/G=17, AA=5; χ2 (2)= 0.21, 
p=0.64), as was CNR1 rs806378 (C/C=18, C/T=24, T/T=3; χ2(2)=1.04, p=0.17) and FAAH rs324420 
(C/C=30, A/C=10 and A/A=4; χ2(2)=4.00, p=0.05). As seen in table 1, participants did not differ on 
demographics based on genotype groupings for CNR1 rs1049353, CNR1 rs806378, or FAAH rs324420. 
Genotype groups differed significantly on the SDS where those who were homozygote GG for the 
CNR1 rs1039353 gene, had a higher cannabis dependence score than A carriers, but groups did not 
differ on cannabis use variables. Additionally, a significant difference was observed for FAAH 
rs324420, between CC homozygotes and A carriers for years of cannabis use. CC homozygotes had 
used cannabis more recently than A carriers.  
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Attentional bias 
CNR1 rs1049353 
There was a drug x genotype interaction (F(3,120)=3.108, p=.029, η²=.03). Within the GG group, 
attentional bias was significantly lower after acute THC administration, in comparison to CBD 
administration (M:25.93, SE: 4.88; p=.011), but this was not significant for the THC+CBD (p=.066), or 
placebo (p=.291) conditions. A carriers show no differences in attentional bias between drug 
administration conditions (p’s=1.000). No Bonferroni-corrected pairwise comparisons met 
significance between genotypes in each drug condition. There was no main effect of drug 
(F(3,120)=2.002, p=.177, η²=.20), stimulus type (F(1,40)=.232, p=.129, η²=.005) or genotype 
(F(1,40)=.723, p=.40, η²=.00) or any other two way or three way interactions.  
 
Figure 2: Mean (±Standard Error) attentional bias, as assessed by the dot probe task, to drug and food 
stimuli (ms) after drug administration for each genotype group. Bonferroni corrected p values are 
displayed.  CNR1 rs1049353 “A” carriers’ attentional bias remains relatively constant whilst GG 
homozygotes vary by cannabinoid administration.  
CNR1 rs806378 
A main effect of genotype emerged (F(1,43)=5.679, p=.022, η²=.047) which showed homozygote CC 
carriers (M:20.21, SE:2.87) had a greater attentional bias than T carriers (M:11.38, SE:2.34), regardless 
of stimuli type and drug. There was no main effect of drug (F(3,129)=1.674, p=.176, η²=.002), stimulus 
type (F(1,43)=.523, p=.474, η²=.00) or other two way or three way interactions. 
FAAH rs324420 
A drug x genotype interaction emerged (F(3,126)=3.385, p=.020, η²=.003). Bonferroni-corrected 
pairwise comparisons reveal lower attentional bias, irrespective of stimuli, between the homozygote 
CC group (M:5.56, SE:3.71) and A carriers (M:21.41, SE:5.42) after THC only (p=0.02). No differences 
emerged between genotype groups for placebo (p=.518), THC+CBD (p=.321) or CBD (p=.261). Within 
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the CC group, there was a significant lower attentional bias after THC in comparison to CBD (M:21.14, 
SE:3.81; p=.018). There was no main effect of drug (F(3,126)=.418, p=.740, η²=.004) or stimulus type 
(F(1,42)=1.089, p=.303, η² =.002) or genotype (F(1,42)=.169, p=.683, η²=.001). There were no other 
two way or three way interactions.  
 
Figure 3: Mean (±Standard Error) attentional bias, as assessed by the dot probe task, after drug 
administration for each genotype group for FAAH rs324420. Bonferroni corrected p values are 
displayed. FAAH rs324420 “A” carriers’ attentional bias remains relatively constant whilst CC 
homozygotes vary by cannabinoid administration.  
BSS “Want to smoke a joint” 
CNR1 rs1049353 
There was a drug x genotype interaction (F(3,105)=4.192, p=.008, η²=.05). The interaction was 
explored with Bonferroni-corrected pairwise comparisons which showed that those with the GG 
genotype had decreased wanting to smoke a joint after both THC (p=.016) and THC+CBD (p<.001), but 
not CBD (p=.137) in comparison to placebo. Those with the A allele did not experience this reduction 
after THC/THC+CBD administration (both p’s=1.000). There was a main effect of drug (F(3,105)=4.206, 
p=.007, η²=.05). Simple contrasts shower lower scores for THC (M:4.73 SE:.41, p=0.047) and for 
THC+CBD (M: 4.45, SE:.42; p=0.001), in comparison to placebo, but not for CBD (M: 4.95, SE:.43; 
0.182). There was a main effect of time (F(1,36)=12.945, p=.001, η²=.03) which showed that wanting 
to smoke a joint increased across the two time-points (p<.001). There was no main effect of genotype 
(F(1,36)= .176, p=.675, η²=0.00), there were no other two-way or three-way interactions.  
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Figure 4: Mean (±Standard Error) of the single item of the Bodily Symptoms Scale: “want to smoke a 
joint” averaged across the two time-points. Bonferroni corrected p values are displayed.  Homozygote 
GG carriers of CNR1 rs1049353 showed reduced wanting after both THC measures, but A carriers show 
no such reduction in state satiety.   
CNR1 rs806378 
There was a main effect of drug (F(3,114)=3.784, p=.012, η²=.005). Simple contrasts show lower 
wanting to smoke a joint after THC (M:4.730, SE:.40; p=.043) and THC+CBD (M:4.55, SE:.43; p=.004) in 
comparison to placebo (M=5.36, SE:.43) but no differences emerged CBD (M:5.06, SE:.43; p=.254). A 
main effect of time emerged (F(1,28)=16.069, p<.001, η²=.04) which showed that wanting to smoke a 
joint increased across the two time-points (p<.001).  There were no main effects or interactions with 
genotype.  
FAAH rs324420  
Only a main effect of time emerged (F(1,27)=11.738, p=.002, η²=.04) which showed that wanting to 
smoke a joint increased across the two time-points (p<.001).   
Marijuana Craving Questionnaire  
CNR1 rs1049353 
There was no main effect of drug, genotype or drug x genotype interaction 
CNR1 rs806378 
There was no main effect of drug, genotype or drug x genotype interaction 
FAAH rs324420 
There was no main effect of drug, genotype or drug x genotype interaction 
Sensitivity analysis  
Because our sampling strategy aimed to include individuals with high and low scores in both schizotypy 
and frequency of cannabis use (Hindocha et al. 2015a; Morgan et al. 2018), we included mean-centred 
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days per month of cannabis use and SPQ scores as continuous covariates into each analysis. Adjusted 
and unadjusted main effects and interactions were generally similar and addition of covariates did not 
modify results. Days per month of cannabis use was seen be a significant covariate in many of the 
analyses (Analyses can be requested from CH). 
Discussion 
This study, to our knowledge, is the first to suggest that the acute effects of different cannabinoids on 
addiction endophenotypes are moderated by genes encoding the CNR1 receptor and FAAH enzyme. 
Specifically we show that individuals who are homozygous GG on the CNR1 rs1049353 SNP show 
reduced wanting to smoke a joint, indicative of increased satiety, after THC and THC+CBD, in 
comparisons to placebo. They also show reduced attentional bias to appetitive stimuli after THC, in 
comparison to CBD. However, A carriers show no changes in attentional bias to acute THC (/THC+CBD) 
administration and did not appear satiated after acute administration of THC. In regards to CNR1 
rs806378, homozygote CC carriers had a greater attentional bias to appetitive stimuli, regardless of 
cue type and drug condition.  Across both CNR1 SNPs, genotype did not modulate craving. 
Variations in the FAAH genotype also modulated attentional bias. Homozygous CC carriers show 
reduced attentional bias to incentive stimuli after THC administration, in comparison to A carriers. 
Homozygous CC carriers also showed reduced attentional bias after THC in comparison to CBD 
administration, suggesting CBD alone is not modulating drug cue salience. However, FAAH genotype 
did not modulate state satiation or craving. These data are very important as acute response to 
cannabis is thought to be a marker of the development of other risks such as addiction and psychosis 
from smoking the drug (Morgan et al. 2016) and may further helps us understand the role of the 
endocannabinoid system in individual differences in risk and resilience for the abuse for cannabis.   
CNR1 genes modify the binding of cannabis and endogenous cannabinoids to the CB1R, thus altering 
the signalling of the endocannabinoid system which is known to play a key role in addiction (Forget et 
al. 2009; López-Moreno et al. 2012; Maldonado et al. 2006; Parsons and Hurd 2015; Scherma et al. 
2016; Sipe et al. 2002). In the brain, CB1Rs are found on GABAergic and glutamatergic interneurons in 
the ventral tegmental area (VTA) where they regulate the mesolimbic dopaminergic pathway leading 
to modulation dopamine release in the nucleus accumbens; a key mechanism in incentive salience 
(Bloomfield et al. 2016; Cheer et al. 2004; Robinson and Berridge 2001). In this study, CNR1 genes 
seem to be modulating cannabis users’ response to acute administration of cannabinoids on putative 
endophenotypes such as appetitive cue salience (Field and Cox 2008) and satiety (Sussman and 
Sussman 2011) but not craving.  It may be that A carriers of the CNR1 rs1049353 are more liable for 
addiction because they did not feel satiety after drug administration as assessed by attentional bias 
and state satiety. In contrast, the GG carriers showed reductions in these endophenotypes in reponse 
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to THC administration, as expected. GG carriers had greater self-reported cannabis dependence, 
however, groups did not differ on other drug use measures such as frequency of use, last use of 
cannabis or years of cannabis use. When we adjusted for frequency of use (a strong predictor of the 
severity of dependence (Curran et al. 2018)), it had no effect on the results, suggesting that this effect 
was not explained by variation in frequency of use.  CC carriers of CNR1 rs806378 showed increased 
bias for both cannabis and food related cues regardless of drug condition suggesting that CC carriers 
may be more susceptible to appetitive cues overall. This SNP has been previously related to cocaine 
dependence. However, no genotype specific effects were seen on state satiety or craving.  
In regards to FAAH, those who are homozygote for the A allele have ~30% poorer FAAH functioning 
and are a minority of the population (5%) (Chiang et al. 2004; Mayo et al. 2018; Sipe et al. 2002). As a 
result, these individuals can be used as a human genetic model of elevations in anandamide which 
may be able to inform whether FAAH inhibitors would have an effect on these intermediate 
endophenotypes (Mayo et al. 2018). Those with the C allele, on the other hand is associated with 
cannabis dependence and related endophenotypes (Filbey et al. 2010; Flanagan et al. 2006; Haughey 
et al. 2008; Schacht et al. 2009). In this study, A carriers showed a greater bias towards incentive 
stimuli in comparison to CC carriers – which would be consistent with some previous research 
suggesting this polymorphism is associated with emotional-motivational reactivity (Conzelmann et al. 
2012) but contradicts others (Hariri et al. 2009). However, A carriers also had significantly fewer years 
of cannabis use; but when we adjusted for cannabis use in the model, this did not change the results. 
In this study, low FAAH functioning may be influencing the automatic processes associated with 
salience of drug cues but did not influence satiation or craving after acute drug administration – which 
are arguably more explicit measures of addiction. 
In genetic association research, there have been equivocal findings with variants in CNR1 and FAAH 
genotypes on cannabis dependence (Agrawal et al. 2012b). Future research should investigate the role 
of genetic variants in the endocannabinoid system on transdiagnostic markers for mental health found 
in the RDoC initiative include neuroimaging and plasma biomarkers - which may be reliable indicators 
(Agrawal et al. 2012b). Additionally, the CNR1 and FAAH genes noted in this study should be 
investigated in relation to other cannabis-related harms such as psychotic-like experiences, 
depression and anxiety as they have already been showed to contribute to psychiatric problems 
(Hillard et al. 2012). Longitudinal studies are imperative to clarify whether genetic variation influences 
cannabis dependence – such is the focus of the ABCD study (Lisdahl et al. 2018). Moreover, the 
development of polygenic risk scores for cannabis dependence that can capture a wider range of 
common genetic variants, should be developed and utilised. 
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Strengths and Limitations  
Strengths of this study, include a controlled design of a four way crossover with THC, CBD and their 
combination on addiction-related outcomes. One criticism levied at genome wide association studies 
(GWAS) is that they tend to utilise a dichotomous diagnostic cut off, such as cannabis dependence 
(Agrawal et al. 2012b; Flint and Munafò 2007; Gottesman and Gould 2003), for which the causes are 
likely to be complex and involve many mechanisms and predictors (van der Pol et al. 2013). The 
National Institute of Mental Health (NIHM) Research Domain criteria (RDoC) initiative supports 
research about the biobehavioural dimensions that cut across these prescriptive diagnostics (Insel 
2014). However, such intermediates or endophenotypes have remain unexplored for addictive 
disorders until recently (Kwako et al. 2016; Yücel et al. 2018). In this study, we took endophenotypes 
that might be more closely related to the disorder than diagnostic criteria which is a strength of this 
study.  However, the sample size of this study was modest and there were unequal numbers of each 
genotype. The sample size calculation was based on the effects of THC, not on genetic differences. It 
would be important to replicate these findings with a larger sample size, oversampling for the minor 
allele and allowing for analysis of a dose-response relationship between genotype and risk (Di Forti et 
al. 2012; Morgan et al. 2016).  
Conclusions 
In conclusion, our experiment suggests that the genes that code for the CB1 receptor and FAAH 
enzyme are implicated in the acute addiction-related response to acute consumption of cannabinoids. 
This was found for attentional bias and state satiety, but not for craving. These results have important 
pharmacogenetic implications in regards to recreational users of cannabis who may be more 
vulnerable to addiction-forming effects of THC and who may therefore be at greater risk of 
transitioning into dependence. 
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Table 1: Means (SD) for demographic, mental health and cannabis use variables for each of the genotype groups.  
 
Notes: a - Welch’s Test, b Includes White Other, mixed white and black Caribbean, mixed white and black African, any other mixed background, Asian/British Asian, any 
other Asian/British Asian background, Black/British Caribbean, Chinese and any other ethnic group, * indicated significant difference at p ≤0.05 
 
 
CNR1 rs1049353 
 
CNR1 rs806378 
 
FAAH rs324420 
 
 
GG AA/AG Test statistic CC CT/TT Test Statistic  CC AA/AC Test statistic  
N (% female) 20 (35%) 22 (27%) χ2(1)=.293, ns 18 
(33.3%) 
27 
(29.7%) 
χ2(1)=.069, ns 30 (23%)  14 (50%) χ2(1)=3.129, ns 
Age 21.90 
(1.94) 
21.59 
(1.94) 
F(1,40)=.265, ns 21.44 
(1.98) 
22.00 
(1.79) 
F(1,43)=.953, ns 21.87 
(1.92) 
21.79 
(1.72) 
F(1,43)=.018, ns 
Race/Ethnicity (self-reported) 
        
White British 14 17 
 
12 20 
 
23 8 
 
Other Ethnic Group 6 5 χ2(1)=.28, ns 6 7 χ2(2)=.005, ns 7 5 χ2(1)=1.03, ns 
Frequency of cannabis 
use 
19.75 
(10.95) 
17.72 
(10.21) 
F(1,40)=.394, ns 20.36 
(10.15) 
17.98 
(10.82) 
F(1,43)=.548, ns 19.53 
(17.21) 
17.21 
(10.21) 
F(1,42)=.452, ns 
Severity of 
Dependence 
4.05 
(3.62) 
2.09 (2.21) F(1,40)=4.585,p=0.038
* 
3.55 
(3.70) 
2.56 
(2.47) 
F(1,43)=1.187, ns 3.47 
(3.26) 
1.71 
(2.16) 
F(1,42)=3.345, ns 
Last use of cannabis  3.25 
(3.17) 
7.81 (25.09 F(1,40)=.652, ns 2.94 
(1.98) 
8.00 
(23.14) 
F(1,43)=.848, ns 2.63 
(1.87) 
13.43 
(31.67) 
W(1,12)=1.624, nsa 
Years of cannabis use 6.80(2.31) 6.02 (3.05) F(1,40)=.854, ns 6.00 
(2.57) 
6.31 
(2.91) 
F(1,43)=.138, ns 6.83 
(2.64) 
4.96 
(2.68) 
F(1,42)=3.557,p=.035* 
SPQ total 19.05 
(12.41) 
16.55 
(15.86) 
F(1,40)=.320, ns 19.83 
(13.43 
15.15 
(14.32) 
F(1,43)=1.214, ns 14.07 
(9.92) 
22.36 
(19.46) 
F(1,42)=3.542, ns 
BDI 13.30 
(9.42) 
7.91 (8.87) F(1,40)=3.651, ns 11.96 
(10.79) 
8.48 
(8.25) 
F(1,43)=1.485, ns 9.23 
(9.16) 
10.79 
(10.32) 
F(1,42)=.253, ns 
STAI 43.50 
(11.40) 
40.41 
(8.81) 
F(1,40)=.976, ns 42.44 
(11.55) 
40.04 
(9.63) 
F(1,43)=.575, ns 40.47 
(10.95) 
42.14 
(10.95) 
F(1,42)=.239, ns 
